Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
BACKGROUND
Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD).


METHODS
A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment.


RESULTS
The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 microm (week 1), 205 microm (week 4), and 171 microm (week 12), respectively (P < 0.0001, for all comparisons). One patient experienced a transient moderate vision loss after 4 weeks post treatment. Leakage on fluorescein angiography was resolved in all patients at week 12. No significant ocular or systemic side-effects were observed.


CONCLUSIONS
Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.
Ladewig
Markus S
MS
Department of Ophthalmology, University of Bonn, Ernst-Abbe-Strasse 2, 53127, Bonn, Germany.
Karl
Stefanie E
SE
Hamelmann
Victoria
V
Helb
Hans-Martin
HM
Scholl
Hendrik P N
HP
Holz
Frank G
FG
Eter
Nicole
N
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003131:Combined Modality Therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D000068258:Bevacizumab
Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1132-42
16538452
Am J Ophthalmol. 2004 Nov;138(5):803-8
15531316
Ophthalmology. 2006 Jan;113(1):14-22
16360209
Ophthalmology. 1996 Mar;103(3):427-38
8600419
Am J Ophthalmol. 2003 Mar;135(3):343-50
12614752
Graefes Arch Clin Exp Ophthalmol. 2003 Jun;241(6):518-21
12734707
Br J Ophthalmol. 2004 Mar;88(3):344-7
14977766
Am J Ophthalmol. 2003 Sep;136(3):407-18
12967792
Arch Ophthalmol. 1999 Sep;117(9):1177-87
10496389
Ophthalmology. 2005 Jun;112(6):1035-47
15936441
Ophthalmology. 2005 Feb;112(2):301-4
15691567
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):371-6
16384987
Invest Ophthalmol Vis Sci. 2003 May;44(5):2147-54
12714655
Arch Ophthalmol. 2002 Jun;120(6):835-44
12049594
Acta Ophthalmol Scand. 2005 Dec;83(6):645-63
16396641
Invest Ophthalmol Vis Sci. 1999 Sep;40(10 ):2322-31
10476799
Ophthalmology. 2003 Aug;110(8):1517-25
12917166
Am J Ophthalmol. 2004 Mar;137(3):504-10
15013875
Klin Monbl Augenheilkd. 2005 May;222(5):390-5
15912456
Graefes Arch Clin Exp Ophthalmol. 2006 Jul;244(7):773-81
16440207
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):357-63
16384985
Mol Vis. 2003 Dec 22;9:747-55
14735062
Arch Ophthalmol. 1999 Oct;117(10 ):1329-45
10532441
Invest Ophthalmol Vis Sci. 2003 Oct;44(10 ):4473-80
14507895
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
16172168
Retina. 2006 Apr;26(4):383-90
16603955
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2389-93
10892888
Retina. 2004 Oct;24(5 Suppl):S3-19
15483476
Ophthalmology. 2006 Mar;113(3):363-372.e5
16458968
Arch Ophthalmol. 2001 Feb;119(2):198-207
11176980
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
16156152
J Clin Invest. 2006 Feb;116(2):422-9
16453023
Arch Ophthalmol. 2005 Apr;123(4):509-16
15824225